Skip to Main Content

Medpace Holdings, Inc. (NASDAQ: MEDP) Securities Fraud Investigation

On October 21, 2024, during after-market hours, Medpace reported its third quarter 2024 financial results and cut its revenue guidance for full-year 2024. During an investor call held on October 22, 2024, Medpace indicated that the company had seen higher-than-normal levels of cancellations in the third quarter. As a result of the cancellations, Medpace’s net book-to-bill ratio, a key indicator of demand, was just 1.00 for the quarter, below analyst estimates and the lowest in Medpace’s history as a public company, according to one Truist analyst.

Following this news, Medpace’s stock price fell over 7%, from a close of $352.92 per share on October 21, 2024, to close at $326.54 per share on October 22, 2024.   

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.  

Complete this form with your transactions in Medpace Holdings, Inc.
 securities between February 13, 2024 and October 21, 2024.

Click Here to Print PDF of this Form

SUBMIT YOUR INFORMATION
* Denotes required field
Purchase(s)
+ Additional Purchases
Sale(s)
+ Additional Sales
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Medpace Holdings, Inc. prior to the Class Period?
Are you a current or former employee of Medpace Holdings, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email
Submit Your Information